Billionaires Bill Gates and Steve Branson have joined Cargill [one of the largest agricultural companies in the world] in investing in Memphis Meats, which has been working to bring accessible, ethical and cruelty free meat to the market. Memphis Meats has successfully grown beef, chicken and duck meat from the animals’ stem cells, providing the same taste and nutrition without any harm to animals. By programming the cells to become muscle tissue, the company has been able to create lab-grown meat with all the biological components of real meat. The cultured meat is said to look and taste exactly like the real deal, but could be even more salubrious for consumption, given that it bypasses the hormones and the unhealthy diets that livestock is often fed.
Researchers at the University of Pennsylvania school of Dental Medicine have elucidated the mechanism behind mesenchymal stem cell transplants in lupus patients, who typically suffer greater risk of osteoporosis. Prior work with stem cells has led to improvements in their condition, but until the current study, the process by which gains were made have been poorly understood.
The potential power of regenerative medicine is gaining prominence in the mainstream media. A recent report in the Wall Street Journal depicts a future where regenerative medicine would support the repair and regeneration of human body parts and tissues via stem cells, three-dimensional printing, and applied bioengineering strategies. The emerging therapies take advantage of the special characteristics of stem cells, that is, their role as the natural repair and maintenance cells of the body and their ability to regenerate and differentiate into a variety of cell types.
Recently published research out of South Korea has presented a new method of differentiating mesenchymal stem cells [MSCs] into liver cells for autologous use in regenerative medicine. Geneticists found that the overexpression of two genes within MSCs, oct4 and sox2, resulted in the stem cells converting into fully functional hepatocytes, or liver cells, capable of producing urea and storing glycogen.
Topics: hepatocytes, liver cells, regenerate organs, Stemcells, stem cell differentiation, Liver disease, research, StemSave, mesenchymal stem cells, autologous stem cells, stem cells, biology, adult stem cells
In a recently published study from the Queen Mary University of London, scientists discovered a connection between the length of cilia [hair-like projections for cell movement] on stem cells and their proclivity towards differentiating into fat cells. By restricting the elongation of stem cell cilia, the researchers were able to impede on the formation of new fat cells.
The New York-based startup Epibone intends to begin human testing on a procedure that will utilize stem cells to regenerate living bone tissue. The researchers, originally from Columbia University, will apply autologous [the patient’s own] stem cells to nanofiber scaffolding of the desired size and shape and direct the stem cells to differentiate into a physical and genetic replica of the patient’s own bone.
Topics: osteoporosis, limbs, Fingers, Jaw, Bone loss, Joints, Bone, Debilitating Diseases, Arthritis, Stemcells, Knee, hip, autologousstemcells, cartilage, grants, Mandibular bone, young stem cells, stemsaveblog
The Multiple Sclerosis Society of Canada has funded Canada’s first stem cell clinical trial to treat multiple sclerosis, conducted by researchers at the University of Ottawa. The trial, called MESCAMS [Mesenchymal Stem Cell Therapy for Canadian MS patients], will comprise MSC infusions to the central nervous system to utilize their ability to regulate autoimmune attacks and reduce inflammation in 40 MS patients.
Topics: ALS, Phase III, neural stem cells, multiple sclerosis, Brain, clinical trials, Debilitating Diseases, Stemcells, autologousstemcells, Amyotrophic lateral sclerosis, Neurodegenerative disease, stemsaveblog
Ophthalmologists James L Funderburgh, Ph.D. and Fatima Syed-Picard, Ph.D. from the University of Pittsburgh have devised a method for treating corneal blindness by utilizing dental pulp stem cells. The researchers harvested the stem cells from molars discarded during routine extraction and induced the cells to differentiate into keratocytes [corneal cells]. They then seeded the cells onto a nanofiber scaffold, allowing them to grow into fully developed, functional corneas capable of restoring eyesight.
In a new two year clinical trial conducted by the University of Miami, researchers will attempt to treat deep second degree burn victims with mesenchymal stem cells [MSCs] as a potential alternative to skin grafts. The team, led by Dr. Evangelos Badiavas, will first cover the wounds in protective dressing, and then inject the MSCs under the dressing and into the wounds to spur the regeneration of the inner and outer layers of skin.
Researchers from Okayama University have developed a method to treat the congenital heart defect known as hypoplastic left heart syndrome [HLHS] by utilizing a specialized cardiac stem cell. In a Phase I clinical trial conducted on children suffering from HLHS, the scientists concluded that, because the young stem cells in children are more abundant and self-renewing than those in adults, intracoronary injection of stem cells is a safe and feasible approach to treating the condition.
Topics: Heart Valve, Phase III, Heart, Heart Failure, Pediatric Congenital Heart Disease, clinical trials, Debilitating Diseases, Stemcells, hypoplastic left heart syndrome, Heart Attack, autologousstemcells, heart disease, stemsaveblog